nach oben

The European Journal of Health Economics

Erschienen in:

04.04.2016 | Original Paper

Social/economic costs and health-related quality of life in patients with histiocytosis in Europe

verfasst von: Georgi Iskrov, Itziar Astigarraga, Rumen Stefanov, Julio López-Bastida, Renata Linertová, Juan Oliva-Moreno, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, Arrigo Schieppati, Domenica Taruscio, Márta Péntek, Johann Matthias Graf von der Schulenburg, Panos Kanavos, Karine Chevreul, Ulf Persson, Giovanni Fattore, BURQOL-RD Research Network

Erschienen in: The European Journal of Health Economics | Sonderheft 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study was to determine the economic burden from a societal perspective and the health-related quality of life (HRQOL) of patients with histiocytosis in Europe.

Methods

We conducted a cross-sectional study of patients with histiocytosis from France, Germany, Italy, Spain, Bulgaria, the UK, and Sweden. Data on demographic characteristics, health resource utilisation, informal care, loss of labour productivity and HRQOL were collected from the questionnaires completed by patients or their caregivers. HRQOL was measured with the EuroQol 5-domain (EQ-5D) questionnaire.

Results

A total of 134 patients (35 France, 32 Germany, 30 Italy, 24 Spain, 7 Bulgaria, 4 UK and 2 Sweden) completed the questionnaire. The average annual costs ranged from € 6832 to € 33,283 between countries, the year of reference being 2012. Estimated direct healthcare costs ranged from € 1698 to € 18,213; direct nonhealthcare costs ranged from € 2936 to € 17,622 and labour productivity losses ranged from € 1 to € 8855. The mean EQ-5D score for adult histiocytosis patients was estimated at between 0.32 and 0.85, and the mean EQ-5D visual analogue scale score was estimated at between 50.00 and 66.50.

Conclusion

The main strengths of this study lie in our bottom-up approach to costing and in the evaluation of histiocytosis patients from a broad perspective (societal costs). This type of analysis is very scarce in international literature for rare diseases in comparison with other illnesses. We conclude that histiocytosis patients incur considerable societal costs and experience substantial deterioration in HRQOL.

Nur mit Berechtigung zugänglich

Hervier, B., Haroche, J., Arnaud, L., Charlotte, F., Donadieu, J., et al.: Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 124, 1119–1126 (2014)CrossRefPubMed

Histiocytosis Association: LCH in Children. http://www.histio.org/lchinchildren#.VJkyssgA. Accessed 23 December 2014

Stålemark, H., Laurencikas, E., Karis, J., Gavhed, D., Fadeel, B., et al.: Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr. Blood Cancer 51, 76–81 (2008)CrossRefPubMed

Mataix, J., Betlloch, I.: Langerhans cell histiocytosis: an update. G. Ital. Dermatol. Venereol. 144, 119–134 (2009)PubMed

Morimoto, A., Oh, Y., Shioda, Y., Kudo, K., Imamura, T.: Recent advances in Langerhans cell histiocytosis. Pediatr. Int. 56, 451–461 (2014)CrossRefPubMed

Wilejto, M., Abla, O.: Langerhans cell histiocytosis and Erdheim-Chester disease. Curr. Opin. Rheumatol. 24, 90–96 (2012)CrossRefPubMed

DiCaprio, M.R., Roberts, T.T.: Diagnosis and Management of Langerhans Cell Histiocytosis. J. Am. Acad. Orthop. Surg. 22, 643–652 (2014)CrossRefPubMed

Martin, A., Macmillan, S., Murphy, D., Carachi, R.: Langerhans cell histiocytosis: 23 years’ paediatric experience highlights severe long-term sequelae. Scott. Med. J. 59, 149–157 (2014)CrossRefPubMed

Aricò, M., Girschikofsky, M., Généreau, T., Klersy, C., McClain, K., et al.: Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur. J. Cancer 39, 2341–2348 (2003)CrossRefPubMed

10.

Girschikofsky, M., Arico, M., Castillo, D., Chu, A., Doberauer, C., et al.: Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet. J. Rare Dis. (2013). doi:10.1186/1750-1172-8-72 PubMedPubMedCentral

11.

Linertová, R., Serrano-Aguilar, P., Posada de la Paz, M., Hens-Pérez, M., Kanavos, P., et al.: Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. Health Policy 108, 19–26 (2012)CrossRefPubMed

12.

Brooks, R.: EuroQol: the current state of play. Health Policy 37, 53–72 (1996)CrossRefPubMed

13.

Drummond, M.F., O’Brien, B., Stoddart, G.L., Torrance, G.W.: Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford (1997)

14.

McDaid, D.: Estimating the costs of informal care for people with Alzheimer’s disease: methodological and practical challenges. Int. J. Geriatr. Psychiatry 16, 400–405 (2001)CrossRefPubMed

15.

Van den Berg, B., Brouwer, W., Koopmanschap, M.: Economic valuation of informal care: an overview of methods and applications. Eur. J. Health Econ 5, 36–45 (2004)CrossRefPubMed

16.

Hodgson, T.A., Meiners, M.R.: Cost-of-illness methodology: a guide to assessment practices and procedures. Milbank Mem Fund Q 60, 429–491 (1982)CrossRef

17.

Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35, 1095–1108 (1997)CrossRefPubMed

18.

Mahoney, F.I., Barthel, D.W.: Functional evaluation: the Barthel Index. Md State Med 14, 61–65 (1965)

19.

Shah, S., Vanclay, F., Cooper, B.: Improving the sensitivity of the Barthel Index for stroke rehabilitation. J. Clin. Epidemiol. 42, 703–709 (1989)CrossRefPubMed

20.

Hérbert, R., Bravo, G., Préville, M.: Reliability, validity, and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia. Can J Aging 19, 494–507 (2000)CrossRef

21.

Imrie, J., Galani, C., Gairy, K., Lock, K., Hunsche, E.: Cost of illness associated with Niemann-Pick disease type C in the UK. J Med. Econ 12, 219–229 (2009)CrossRefPubMed

22.

Klein, A.D., Alvarez, A., Zanlungo, S.: The unique case of the Niemann-Pick type C cholesterol storage disorder. Pediatr. Endocrinol. Rev. 12, 166–175 (2014)PubMed

23.

Kirchhoff, A.C., Fluchel, M.N., Wright, J., Ying, J., Sweeney, C., et al.: Risk of hospitalization for survivors of childhood and adolescent cancer. Cancer Epidemiol Biomarkers Prev 23, 1280–1289 (2014)CrossRefPubMed

24.

Audino, A.N., Yeager, N.D., Asti, L., Miao, Y., O’Brien, S.H.: Length of stay and treatment-related complications are similar in pediatric and AYA patients with bone sarcoma in United States children’s hospitals. Pediatr. Blood Cancer 60, 415–419 (2012)CrossRefPubMed

25.

Warner, E.L., Kirchhoff, A.C., Nam, G.E., Fluchel, M.: Financial Burden of Pediatric Cancer for Patients and Their Families. J Oncol Pract (2014)

26.

Wakefield, C.E., McLoone, J.K., Evans, N.T., Ellis, S.J., Cohn, R.J.: It’s more than dollars and cents: the impact of childhood cancer on parents’ occupational and financial health. J. Psychosoc. Oncol. 32, 602–621 (2014)CrossRefPubMed

27.

Fluchel, M.N., Kirchhoff, A.C., Bodson, J., Sweeney, C., Edwards, S.L.: Geography and the burden of care in pediatric cancers. Pediatr. Blood Cancer 61, 1918–1924 (2014)CrossRefPubMedPubMedCentral

28.

Kirchhoff, A.C., Lyles, C.R., Fluchel, M., Wright, J., Leisenring, W.: Limitations in health care access and utilization among long-term survivors of adolescent and young adult cancer. Cancer 118, 5964–5972 (2012)CrossRefPubMed

29.

Dussel, V., Bona, K., Heath, J.A., Hilden, J.M., Weeks, J.C., et al.: Unmeasured costs of a child’s death: perceived financial burden, work disruptions, and economic coping strategies used by American and Australian families who lost children to cancer. J. Clin. Oncol. 29, 1007–1013 (2011)CrossRefPubMed

30.

Vrijmoet-Wiersma, C.M., Kooloos, V.M., Koopman, H.M., Kolk, A.M., van der Laan, I., et al.: Health-related quality of life, cognitive functioning and behaviour problems in children with Langerhans cell histiocytosis. Pediatr. Blood Cancer 52, 116–122 (2009)CrossRefPubMed

31.

Nanduri, V.R., Pritchard, J., Levitt, G., Glaser, A.W.: Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis. Eur. J. Cancer 42, 2563–2569 (2006)CrossRefPubMed

32.

Lau, L.M., Stuurman, K., Weitzman, S.: Skeletal Langerhans cell histiocytosis in children: permanent consequences and health-related quality of life in long-term survivors. Pediatr. Blood Cancer 50, 607–612 (2008)CrossRefPubMed

33.

Laurencikas, E., Gavhed, D., Stålemark, H., van’t Hooft, I., Prayer, D., et al.: Incidence and pattern of radiological central nervous system Langerhans cell histiocytosis in children: a population based study. Pediatr. Blood Cancer 56, 250–257 (2011)CrossRefPubMed

34.

Vassallo, R., Ryu, J.H., Schroeder, D.R., Decker, P.A., Limper, A.H.: Clinical outcomes of pulmonary Langerhans’-cell histiocytosis in adults. N. Engl. J. Med. 346, 484–490 (2002)CrossRefPubMed

35.

Koopman, H.M., Koetsier, J.A., Taminiau, A.H., Hijnen, K.E., Bresters, D., et al.: Health-related quality of life and coping strategies of children after treatment of a malignant bone tumor: a 5-year follow-up study. Pediatr. Blood Cancer 45, 694–699 (2005)CrossRefPubMed

36.

Simms, S., Warner, N.J.: A framework for understanding and responding to the psychosocial needs of children with Langerhans cell histiocytosis and their families. Hematol. Oncol. Clin. North Am. 12, 359–367 (1998)CrossRefPubMed

37.

Mason, R.H., Foley, N.M., Branley, H.M., Adamali, H.I., Hetzel, M., et al.: Pulmonary Langerhans cell histiocytosis (PLCH): a new UK register. Thorax 69, 766–767 (2014)CrossRefPubMed

38.

Taruscio, D., Gentile, A.E., Evangelista, T., Frazzica, R.G., Bushby, K., et al.: Centres of Expertise and European Reference Networks: key issues in the field of rare diseases. The EUCERD Recommendations. Blood Transfus Suppl 3, 621–625 (2014)

39.

Suri, H.S., Yi, E.S., Nowakowski, G.S., Vassallo, R.: Pulmonary langerhans cell histiocytosis. Orphanet. J. Rare Dis (2012). doi:10.1186/1750-1172-7-16 PubMedPubMedCentral

Titel: Social/economic costs and health-related quality of life in patients with histiocytosis in Europe
verfasst von: Georgi Iskrov
Itziar Astigarraga
Rumen Stefanov
Julio López-Bastida
Renata Linertová
Juan Oliva-Moreno
Pedro Serrano-Aguilar
Manuel Posada-de-la-Paz
Arrigo Schieppati
Domenica Taruscio
Márta Péntek
Johann Matthias Graf von der Schulenburg
Panos Kanavos
Karine Chevreul
Ulf Persson
Giovanni Fattore
BURQOL-RD Research Network
Publikationsdatum: 04.04.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: The European Journal of Health Economics / Ausgabe Sonderheft 1/2016
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-016-0790-5

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2016

Social/economic costs and quality of life in patients with haemophilia in Europe

Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe

Social/economic costs and health-related quality of life in patients with rare diseases in Europe

Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe

Social/economic costs and health-related quality of life in patients with scleroderma in Europe

Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe